Peptide antibiotics

Robert E.W. Hancock

doi:10.1016/S0140-6736(97)80051-7

Peptide antibiotics

Robert E.W. Hancock

Research output: Contribution to journal › Review article › peer-review

1207 Citations (Scopus)

Abstract

The era of the 'classical antibiotic' may be over. The emergence of resistance has seen to that. Yet no truly novel class of antibacterial agent has come on the market in the past 30 years. Currently there is great interest in peptide antibiotics, especially the cationic peptides. Thousands of such molecules have been synthesised and just a few are entering clinical trials. Because they kill bacteria quickly by the physical disruption of cell membranes, peptide antibiotics may not face the rapid emergence of resistance.

Original language	English
Pages (from-to)	418-422
Number of pages	5
Journal	Lancet
Volume	349
Issue number	9049
DOIs	https://doi.org/10.1016/S0140-6736(97)80051-7
Publication status	Published or Issued - 8 Feb 1997
Externally published	Yes

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/S0140-6736(97)80051-7

Cite this

@article{0a6bdecc71f24a3cbabd571ae8bb3edd,

title = "Peptide antibiotics",

abstract = "The era of the 'classical antibiotic' may be over. The emergence of resistance has seen to that. Yet no truly novel class of antibacterial agent has come on the market in the past 30 years. Currently there is great interest in peptide antibiotics, especially the cationic peptides. Thousands of such molecules have been synthesised and just a few are entering clinical trials. Because they kill bacteria quickly by the physical disruption of cell membranes, peptide antibiotics may not face the rapid emergence of resistance.",

author = "Hancock, \{Robert E.W.\}",

note = "Funding Information: My cationic peptide research was initiated with funding from the Canadian Bacterial Diseases Network and the Medical Research Council of Canada, and is currently also sponsored by the Canadian Cystic Fibrosis Foundation's SPARx program and by Micrologix Biotech Inc. ",

year = "1997",

month = feb,

day = "8",

doi = "10.1016/S0140-6736(97)80051-7",

language = "English",

volume = "349",

pages = "418--422",

journal = "Lancet",

issn = "0140-6736",

publisher = "Elsevier B.V.",

number = "9049",

}

TY - JOUR

T1 - Peptide antibiotics

AU - Hancock, Robert E.W.

N1 - Funding Information: My cationic peptide research was initiated with funding from the Canadian Bacterial Diseases Network and the Medical Research Council of Canada, and is currently also sponsored by the Canadian Cystic Fibrosis Foundation's SPARx program and by Micrologix Biotech Inc.

PY - 1997/2/8

Y1 - 1997/2/8

N2 - The era of the 'classical antibiotic' may be over. The emergence of resistance has seen to that. Yet no truly novel class of antibacterial agent has come on the market in the past 30 years. Currently there is great interest in peptide antibiotics, especially the cationic peptides. Thousands of such molecules have been synthesised and just a few are entering clinical trials. Because they kill bacteria quickly by the physical disruption of cell membranes, peptide antibiotics may not face the rapid emergence of resistance.

AB - The era of the 'classical antibiotic' may be over. The emergence of resistance has seen to that. Yet no truly novel class of antibacterial agent has come on the market in the past 30 years. Currently there is great interest in peptide antibiotics, especially the cationic peptides. Thousands of such molecules have been synthesised and just a few are entering clinical trials. Because they kill bacteria quickly by the physical disruption of cell membranes, peptide antibiotics may not face the rapid emergence of resistance.

UR - https://www.scopus.com/pages/publications/0031039956

U2 - 10.1016/S0140-6736(97)80051-7

DO - 10.1016/S0140-6736(97)80051-7

M3 - Review article

C2 - 9033483

AN - SCOPUS:0031039956

SN - 0140-6736

VL - 349

SP - 418

EP - 422

JO - Lancet

JF - Lancet

IS - 9049

ER -

Peptide antibiotics

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this